Invention Grant
- Patent Title: Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
-
Application No.: US13874147Application Date: 2013-04-30
-
Publication No.: US10729672B2Publication Date: 2020-08-04
- Inventor: Laurence Moore , Charles Zacharchuk , Sridhar K. Rabindran
- Applicant: Wyeth LLC
- Applicant Address: US NY New York
- Assignee: Wyeth LLC
- Current Assignee: Wyeth LLC
- Current Assignee Address: US NY New York
- Agency: Jones Day
- Main IPC: A61K31/337
- IPC: A61K31/337 ; A61K31/436 ; A61K31/4709 ; A61K45/06 ; A61K31/4745 ; A61K39/395
Abstract:
A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
Public/Granted literature
- US20140050721A1 Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272 Public/Granted day:2014-02-20
Information query
